CompBrief BY VELARION

Companies Generation Bio Co.

Generation Bio CEO salary & total pay, FY2024: $1.8M

Generation Bio (GBIO) CEO salary, fiscal 2024: Geoff McDonough was paid a salary of $655,301 and $1,808,274 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Generation Bio Co.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Geoff McDonough's complete compensation dossier

A PDF and a CSV sent to your email: Geoff McDonough's pay in every fiscal year Generation Bio Co. reported it, line by line, with Geoff McDonough's equity grants and Generation Bio Co.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$1,808,274CEO Geoff McDonough · source
Say-on-pay support99.06%Latest vote · source
CEO vs. named peers8th pct.Of 16 peer CEOs
CEO pay ratio8:1To the median employee · source

CEO pay, last three years

  • $3,966,762FY2022
  • $2,315,263FY2023
  • $1,808,274FY2024

CEO total pay was $1,808,274 in fiscal 2024, down from $2,315,263 in fiscal 2023.

FY2024: salary $655,301 · bonus $0 · stock awards $0 · option awards $790,358

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Generation Bio Co. in fiscal 2024?
As disclosed, Geoff McDonough (President and Chief Executive Officer) was the highest-paid executive at Generation Bio Co. in fiscal 2024, with total compensation of $1,808,274.
How does Generation Bio Co.'s chief executive pay compare to its disclosed peer group?
As disclosed, Geoff McDonough's total compensation ranked at the 8th percentile of Generation Bio Co.'s disclosed peer group.
What is Generation Bio Co.'s CEO-to-median employee pay ratio?
As disclosed, Generation Bio Co.'s CEO-to-median employee pay ratio was 8:1.
How did shareholders vote on Generation Bio Co.'s executive compensation?
As disclosed, 99.06% of shareholders supported Generation Bio Co.'s executive compensation in the latest say-on-pay vote.
How much does Generation Bio Co. spend in total on board compensation for fiscal 2024?
As disclosed, Generation Bio Co. reported total board compensation of $466,000 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Geoff McDonough$655,301$0$0$790,358$360,416$0$2,199$1,808,274
President and Chief Executive Officer
Matthew Stanton519,16700250,807207,667015,397993,038
Chief Scientific Officer
Antionette Paone475,14100250,807190,056015,958931,962
Chief Operating Officer
Phillip Samayoa475,00000250,807190,000015,956931,763
Chief Strategy Officer
Matthew Norkunas472,44200250,807188,97702,020914,246
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Geoff McDonough$1,808,274$2,315,263$3,966,762↓ −506,989
Matthew Stanton993,0381,151,3381,615,614↓ −158,300
Antionette Paone931,9621,070,0981,582,356↓ −138,136
Phillip Samayoa931,763914,8741,482,616↑ +16,889
Matthew Norkunas914,2461,144,3311,571,892↓ −230,085

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The goals of our compensation programs are to pay for performance and ensure that the interests of our employees, including our NEOs, are aligned with the interests of our stockholders and our business goals, and that the total compensation paid to each of our NEOs is fair, reasonable, and competitive. We aim to target the 50th percentile of our peer group for each compensation element for our NEOs.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantCompensia
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Antionette PaoneOPTION2024-01-02——160,650—$250,807
Matthew NorkunasOPTION2024-01-02——160,650—250,807
Geoff McDonoughOPTION2024-01-02——506,250—790,358
Matthew StantonOPTION2024-01-02——160,650—250,807
Phillip SamayoaOPTION2024-01-02——160,650—250,807

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Antionette Paone$0$0$250,8070.0%
Matthew Norkunas00250,8070.0%
Geoff McDonough00790,3580.0%
Matthew Stanton00250,8070.0%
Phillip Samayoa00250,8070.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Antionette PaoneOption29,5321,96830.25—
Antionette PaoneOption45,37520,6256.49—
Antionette PaoneOption75,62534,3755.23—
Antionette PaoneOption22,28628,6494.71—
Antionette PaoneOption38,15638,1541.39—
Antionette PaoneOption—160,6501.86—
Antionette PaoneRSU—14,324—15,183
Antionette PaoneOption105,230—4.59—
Antionette PaoneOption53,784—5.16—
Antionette PaoneOption14,153—5.16—
Geoff McDonoughOption235,31315,68730.25—
Geoff McDonoughOption257,815117,1856.49—
Geoff McDonoughOption73,82994,9214.71—
Geoff McDonoughOption120,236120,2341.39—
Geoff McDonoughOption—506,2501.86—
Geoff McDonoughRSU—47,459—50,307
Geoff McDonoughOption199,038—5.16—
Matthew NorkunasOption30,7722,05130.25—
Matthew NorkunasOption5,71938130.73—
Matthew NorkunasOption81,81537,1856.49—
Matthew NorkunasOption23,42930,1214.71—
Matthew NorkunasOption38,15638,1541.39—
Matthew NorkunasOption—160,6501.86—
Matthew NorkunasRSU—16,732—17,736
Matthew NorkunasOption330,000—21.41—
Matthew StantonOption68,9074,59330.25—
Matthew StantonOption28,1251,87530.73—
Matthew StantonOption81,81537,1856.49—
Matthew StantonOption23,42930,1214.71—
Matthew StantonOption38,15638,1541.39—
Matthew StantonOption—160,6501.86—
Matthew StantonRSU—15,059—15,963
Matthew StantonOption16,422—0.6—
Matthew StantonOption85,577—4.59—
Matthew StantonOption49,255—5.16—
Phillip SamayoaOption20,6251,37530.25—
Phillip SamayoaOption26,2503,75035.66—
Phillip SamayoaOption40,36118,3456.49—
Phillip SamayoaOption61,87548,1255.53—
Phillip SamayoaOption16,05420,6374.71—
Phillip SamayoaOption38,15638,1541.39—
Phillip SamayoaOption—160,6501.86—
Phillip SamayoaRSU—10,317—10,936
Phillip SamayoaOption6,750—4.59—
Phillip SamayoaOption21,406—5.16—
Phillip SamayoaOption5,500—29.38—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Jason RhodesIndependent · Board Chair · Talent Committee (Chair)$85,000$0$166,476——$251,476
Charles RowlandIndependent · Audit Committee (Chair)55,0000166,476——221,476
Ron CooperIndependent · Nominating and Corporate Governance Committee (Chair)48,0000166,476——214,476
Anthony Quinn, M.B. Ch.B., Ph.DIndependent · Audit Committee47,5000166,476——213,976
Gustav ChristensenIndependent · Audit Committee47,5000166,476——213,976
Donald Nicholson, Ph.DIndependent · Talent Committee47,5000166,476——213,976
Catherine Stehman-Breen, M.DIndependent · Talent Committee47,5000166,476——213,976
Jeffrey Jonas, M.DIndependent · Nominating and Corporate Governance Committee44,0000166,476——210,476
Dannielle AppelhansIndependent · Nominating and Corporate Governance Committee44,0000166,476——210,476
Geoff McDonough, M.DEmployee director—————0

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)7,500 / 7,500 / 4,000
Stock ownership guideline—

Total cost of the board

ComponentFY2024
Cash retainers and fees$466,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$466,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Generation Bio as a peer

Companies that benchmark against GBIO

1 company names GBIO as a compensation peer

Each company listed discloses GBIO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GBIO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Peer reciprocity

The companies Generation Bio Co. names as compensation peers that name it back in their own disclosed peer groups.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Verve Therapeutics, Inc.2024Sekar Kathiresan$639,231$1,683,000$4,727,372$378,972$7,442,663
2Graphite Bio, Inc.2025Evert Schimmelpennink690,00005,793,809538,2007,036,009
3Cartesian Therapeutics, Inc.2025Carsten Brunn674,000973,4752,314,320363,9604,329,868
4Entrada Therapeutics, Inc.2025Dipal Doshi635,0001,387,4281,452,059349,2503,837,737
5Poseida Therapeutics, Inc.2023Mark Gergen611,6671,442,2851,413,936336,4203,818,018
6Sana Biotechnology, Inc.2025Steven Harr696,140425,0011,327,500450,3692,903,010
7Voyager Therapeutics, Inc.2025Alfred Sandrock674,903611,900843,900361,9172,508,370
8Cabaletta Bio, Inc.2025Steven Nichtberger659,55001,266,978446,9822,401,555
9Editas Medicine, Inc.2025Gilmore O'Neill686,57401,282,937375,1642,353,655
10Precision BioSciences, Inc.2025Michael Amoroso650,8751,025,086002,189,467
11Tenaya Therapeutics, Inc.2025Faraz Ali664,173141,924755,507319,2751,881,396
12Caribou Biosciences, Inc.2025Rachel Haurwitz667,534192,818654,54101,840,965
13Generation Bio Co.2024Geoff McDonough655,3010790,358360,4161,808,274
14Adicet Bio, Inc.2025Chen Schor646,2940512,079284,5921,465,747
—2seventy bio, Inc.——————not in coverage universe
—Omega Therapeutics, Inc.——————not in coverage universe

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Generation Bio Co.not disclosednot disclosednot disclosedCompensia
2seventy bio, Inc.not disclosednot disclosednot disclosednot disclosed
Adicet Bio, Inc.not disclosednot disclosednot disclosedAon Consulting, Inc.
Cabaletta Bio, Inc.not disclosedOption 100not disclosedAon
Caribou Biosciences, Inc.not disclosednot disclosednot disclosedAlpine Rewards, LLC
Cartesian Therapeutics, Inc.not disclosednot disclosednot disclosedCompensia
Editas Medicine, Inc.91%Option 100not disclosedPearl Meyer & Partners, LLC
Entrada Therapeutics, Inc.not disclosednot disclosedNoPay Governance
Graphite Bio, Inc.130%Option 100not disclosedAon
Omega Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed
Poseida Therapeutics, Inc.100%not disclosednot disclosedAon Consulting, Inc.
Precision BioSciences, Inc.115%RSU 100not disclosedAon
Sana Biotechnology, Inc.107.5%not disclosednot disclosedAon plc (Human Capital Solutions practice)
Tenaya Therapeutics, Inc.not disclosednot disclosednot disclosedPearl Meyer
Verve Therapeutics, Inc.not disclosednot disclosednot disclosedRadford Data & Analytics from Aon plc
Voyager Therapeutics, Inc.97.5%not disclosedNoAlpine Rewards, LLC

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-06-0438,082,392359,91222,11299.06%Passed
20242024-06-0647,772,176373,24615,12599.22%Passed
20232023-06-0857,779,16294,30215,03399.84%Passed
20212021-06-09—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20252025-06-0499.06%a
20242024-06-0699.22%b
20232023-06-0899.84%c

a. Approved under the standard stated in the filing — “To approve Proposal 3, stockholders holding a majority of the votes cast on the matter must vote FOR the proposal. || If you vote to ABSTAIN on Proposal 3, your shares will not be voted FOR or AGAINST the proposal and will also not be counted as votes cast or shares voting on Proposal 3. As a result, broker non-votes and voting to ABSTAIN will have no effect on the voting on Proposal 3.”.

b. Approved under the standard stated in the filing — “To approve Proposal 3, stockholders holding a majority of the votes cast on the matter must vote FOR the proposal. || If you vote to ABSTAIN on Proposal 3, your shares will not be voted FOR or AGAINST the proposal and will also not be counted as votes cast or shares voting on Proposal 3. As a result, broker non-votes and voting to ABSTAIN will have no effect on the voting on Proposal 3.”.

c. Approved under the standard stated in the filing — “To approve Proposal 4, stockholders holding a majority of the votes cast on the matter must vote FOR the proposal. || If you vote to ABSTAIN on Proposal 4, your shares will not be voted FOR or AGAINST the proposal and will also not be counted as votes cast or shares voting on Proposal 4. As a result, broker non-votes and voting to ABSTAIN will have no effect on the voting on Proposal 4.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)8 : 1
CEO total compensation$1,808,274
Median employee compensation$218,104
Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Dannielle AppelhansDirector2025-06-04A30,000$0$0Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Ron CooperDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2025-07-15D5,27300Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2025-07-15D1,5480659CommonForm 4 ↗
Geoff McDonoughDirector2025-07-15A5,273——CommonForm 4 ↗
Dividend-equivalent accruals2025-07-15—3,326——3 insiders, 3 accrual rows
Phillip SamayoaChief Scientific Officer2025-07-15D3370144CommonForm 4 ↗
Phillip SamayoaChief Scientific Officer2025-07-15A1,147——CommonForm 4 ↗
Antionette PaoneChief Operating Officer2025-07-15D4680199CommonForm 4 ↗
Antionette PaoneChief Operating Officer2025-07-15A1,592——CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2025-07-15D173074CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2025-07-15A587——CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2025-07-15D3,34700Derivative, Class A CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2025-07-15D9830419CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2025-07-15A3,347——CommonForm 4 ↗
Dividend-equivalent accruals2025-10-15—1,192——5 insiders, 5 accrual rows
Kevin John ConwayChief Financial Officer2025-10-15D187121CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2025-10-15A58——CommonForm 4 ↗
Antionette PaoneChief Operating Officer2025-10-15D477315CommonForm 4 ↗
Antionette PaoneChief Operating Officer2025-10-15A159——CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2025-10-15D997664CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2025-10-15A334——CommonForm 4 ↗
Geoff McDonoughDirector2025-10-15D15571,040CommonForm 4 ↗
Geoff McDonoughDirector2025-10-15A527——CommonForm 4 ↗
Phillip SamayoaChief Scientific Officer2025-10-15D347228CommonForm 4 ↗
Phillip SamayoaChief Scientific Officer2025-10-15A114——CommonForm 4 ↗
Dividend-equivalent accruals2025-10-31—659——1 insider, 1 accrual row
Geoff McDonoughDirector2025-10-31D29361,614CommonForm 4 ↗
Geoff McDonoughDirector2025-10-31A659——CommonForm 4 ↗
Dividend-equivalent accruals2026-01-15—789——3 insiders, 3 accrual rows
Kevin John ConwayChief Financial Officer2026-01-15D17696CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-01-15A59——CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2026-01-15D996558CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2026-01-15A335——CommonForm 4 ↗
Geoff McDonoughDirector2026-01-15D1376773CommonForm 4 ↗
Geoff McDonoughDirector2026-01-15A395——CommonForm 4 ↗
Dividend-equivalent accruals2026-02-02—3,490——3 insiders, 3 accrual rows
Yalonda HowzeInterim CEO & President2026-02-02D49562,792CommonForm 4 ↗
Yalonda HowzeInterim CEO & President2026-02-02A1,673——CommonForm 4 ↗
Geoff McDonoughDirector2026-02-02D55063,102CommonForm 4 ↗
Geoff McDonoughDirector2026-02-02A1,582——CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-02D726406CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-02A235——CommonForm 4 ↗
Dannielle AppelhansDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Dannielle AppelhansDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Dannielle AppelhansDirector2026-02-09D3,840——Derivative, Class A CommonForm 4 ↗
Dannielle AppelhansDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Dannielle AppelhansDirector2026-02-09D736——CommonForm 4 ↗
Dannielle AppelhansDirector2026-02-09D1,263——CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D13,142——CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D1,763——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D550——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D1,877——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D35,525——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D249——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D200——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D5,940——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D2,800——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D2,585——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D1,399——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D621——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D1,061——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D283——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D1,192——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D2,072——CommonForm 4 ↗
Ron CooperDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Ron CooperDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Ron CooperDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Ron CooperDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Ron CooperDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Ron CooperDirector2026-02-09D950——CommonForm 4 ↗
Yalonda HowzeInterim CEO and President2026-02-09D7,630——Derivative, Class A CommonForm 4 ↗
Yalonda HowzeInterim CEO and President2026-02-09D25,102——Derivative, Class A CommonForm 4 ↗
Yalonda HowzeInterim CEO and President2026-02-09D11,883——Derivative, Class A CommonForm 4 ↗
Yalonda HowzeInterim CEO and President2026-02-09D10,710——Derivative, Class A CommonForm 4 ↗
Yalonda HowzeInterim CEO and President2026-02-09D3,759——CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D4,246——Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D24,046——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D16,874——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D90,168——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D50,624——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D37,499——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D25,099——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D19,903——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D27,500——CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D22,646——CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D138,492——CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D21,357——CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D7,283——CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D29,928——CommonForm 4 ↗
Jason RhodesDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-02-09D60——CommonForm 4 ↗
Jason RhodesDirector2026-02-09D116,693——CommonForm 4 ↗
Jason RhodesDirector2026-02-09D711,193——CommonForm 4 ↗
Charles RowlandDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D4,246——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D53,475——CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D4,752——CommonForm 4 ↗
Atlas Venture Fund X, L.P.Greater-than-10% holder2026-02-09D60——CommonForm 4 ↗
Atlas Venture Fund X, L.P.Greater-than-10% holder2026-02-09D116,693——CommonForm 4 ↗
Atlas Venture Fund X, L.P.Greater-than-10% holder2026-02-09D711,193——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 158 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Dannielle AppelhansDirector2025-06-04A30,000$0$0Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Ron CooperDirector2025-06-04A30,00000Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2025-07-15D5,27300Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2025-07-15D1,5480659CommonForm 4 ↗
Geoff McDonoughDirector2025-07-15A5,273——CommonForm 4 ↗
Phillip SamayoaChief Scientific Officer2025-07-15D1,14700Derivative, Class A CommonForm 4 ↗
Phillip SamayoaChief Scientific Officer2025-07-15D3370144CommonForm 4 ↗
Phillip SamayoaChief Scientific Officer2025-07-15A1,147——CommonForm 4 ↗
Antionette PaoneChief Operating Officer2025-07-15D1,59200Derivative, Class A CommonForm 4 ↗
Antionette PaoneChief Operating Officer2025-07-15D4680199CommonForm 4 ↗
Antionette PaoneChief Operating Officer2025-07-15A1,592——CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2025-07-15D58700Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2025-07-15D173074CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2025-07-15A587——CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2025-07-15D3,34700Derivative, Class A CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2025-07-15D9830419CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2025-07-15A3,347——CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2025-10-15D5800Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2025-10-15D187121CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2025-10-15A58——CommonForm 4 ↗
Antionette PaoneChief Operating Officer2025-10-15D15900Derivative, Class A CommonForm 4 ↗
Antionette PaoneChief Operating Officer2025-10-15D477315CommonForm 4 ↗
Antionette PaoneChief Operating Officer2025-10-15A159——CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2025-10-15D33400Derivative, Class A CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2025-10-15D997664CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2025-10-15A334——CommonForm 4 ↗
Geoff McDonoughDirector2025-10-15D52700Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2025-10-15D15571,040CommonForm 4 ↗
Geoff McDonoughDirector2025-10-15A527——CommonForm 4 ↗
Phillip SamayoaChief Scientific Officer2025-10-15D11400Derivative, Class A CommonForm 4 ↗
Phillip SamayoaChief Scientific Officer2025-10-15D347228CommonForm 4 ↗
Phillip SamayoaChief Scientific Officer2025-10-15A114——CommonForm 4 ↗
Geoff McDonoughDirector2025-10-31D65900Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2025-10-31D29361,614CommonForm 4 ↗
Geoff McDonoughDirector2025-10-31A659——CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-01-15D5900Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-01-15D17696CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-01-15A59——CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2026-01-15D33500Derivative, Class A CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2026-01-15D996558CommonForm 4 ↗
Yalonda HowzeChief Legal Officer2026-01-15A335——CommonForm 4 ↗
Geoff McDonoughDirector2026-01-15A39500Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-01-15D1376773CommonForm 4 ↗
Geoff McDonoughDirector2026-01-15A395——CommonForm 4 ↗
Yalonda HowzeInterim CEO & President2026-02-02D1,67300Derivative, Class A CommonForm 4 ↗
Yalonda HowzeInterim CEO & President2026-02-02D49562,792CommonForm 4 ↗
Yalonda HowzeInterim CEO & President2026-02-02A1,673——CommonForm 4 ↗
Geoff McDonoughDirector2026-02-02D1,58200Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-02D55063,102CommonForm 4 ↗
Geoff McDonoughDirector2026-02-02A1,582——CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-02D23500Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-02D726406CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-02A235——CommonForm 4 ↗
Dannielle AppelhansDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Dannielle AppelhansDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Dannielle AppelhansDirector2026-02-09D3,840——Derivative, Class A CommonForm 4 ↗
Dannielle AppelhansDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Dannielle AppelhansDirector2026-02-09D736——CommonForm 4 ↗
Dannielle AppelhansDirector2026-02-09D1,263——CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Gustav ChristensenDirector2026-02-09D13,142——CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D1,763——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D550——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D1,877——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D35,525——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D249——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D200——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D5,940——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D2,800——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D2,585——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D1,399——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D621——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D1,061——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D283——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D1,192——Derivative, Class A CommonForm 4 ↗
Kevin John ConwayChief Financial Officer2026-02-09D2,072——CommonForm 4 ↗
Ron CooperDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Ron CooperDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Ron CooperDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Ron CooperDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Ron CooperDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Ron CooperDirector2026-02-09D950——CommonForm 4 ↗
Yalonda HowzeInterim CEO and President2026-02-09D7,630——Derivative, Class A CommonForm 4 ↗
Yalonda HowzeInterim CEO and President2026-02-09D25,102——Derivative, Class A CommonForm 4 ↗
Yalonda HowzeInterim CEO and President2026-02-09D11,883——Derivative, Class A CommonForm 4 ↗
Yalonda HowzeInterim CEO and President2026-02-09D10,710——Derivative, Class A CommonForm 4 ↗
Yalonda HowzeInterim CEO and President2026-02-09D3,759——CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D4,246——Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D24,046——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D16,874——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D90,168——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D50,624——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D37,499——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D25,099——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D19,903——Derivative, Class A CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D27,500——CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D22,646——CommonForm 4 ↗
Geoff McDonoughDirector2026-02-09D138,492——CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Donald William NicholsonDirector2026-02-09D21,357——CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D7,283——CommonForm 4 ↗
Anthony G. QuinnDirector2026-02-09D29,928——CommonForm 4 ↗
Jason RhodesDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Jason RhodesDirector2026-02-09D60——CommonForm 4 ↗
Jason RhodesDirector2026-02-09D116,693——CommonForm 4 ↗
Jason RhodesDirector2026-02-09D711,193——CommonForm 4 ↗
Charles RowlandDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D4,246——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Charles RowlandDirector2026-02-09D53,475——CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D6,000——Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D2,500——Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D1,920——Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D1,500——Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D5,200——Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D3,000——Derivative, Class A CommonForm 4 ↗
Catherine Stehman-BreenDirector2026-02-09D4,752——CommonForm 4 ↗
Atlas Venture Fund X, L.P.Greater-than-10% holder2026-02-09D60——CommonForm 4 ↗
Atlas Venture Fund X, L.P.Greater-than-10% holder2026-02-09D116,693——CommonForm 4 ↗
Atlas Venture Fund X, L.P.Greater-than-10% holder2026-02-09D711,193——CommonForm 4 ↗
Sources (200 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Geoff McDonough. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 1,808,274. View filing ↗
  • Section 01, Matthew Stanton. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 993,038. View filing ↗
  • Section 01, Antionette Paone. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 931,962. View filing ↗
  • Section 01, Phillip Samayoa. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 931,763. View filing ↗
  • Section 01, Matthew Norkunas. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 914,246. View filing ↗
  • Section 03, Antionette Paone OPTION. DEF 14A, filed 2025-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Matthew Norkunas OPTION. DEF 14A, filed 2025-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Geoff McDonough OPTION. DEF 14A, filed 2025-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Matthew Stanton OPTION. DEF 14A, filed 2025-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Phillip Samayoa OPTION. DEF 14A, filed 2025-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 07, pay ratio. DEF 14A, filed 2025-04-23. Section “CEO Pay Ratio”. As printed: 8 : 1. View filing ↗
  • Section 08, Jason Rhodes. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 251,476. View filing ↗
  • Section 08, Charles Rowland. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 221,476. View filing ↗
  • Section 08, Ron Cooper. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 214,476. View filing ↗
  • Section 08, Anthony Quinn, M.B. Ch.B., Ph.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 213,976. View filing ↗
  • Section 08, Gustav Christensen. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 213,976. View filing ↗
  • Section 08, Donald Nicholson, Ph.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 213,976. View filing ↗
  • Section 08, Catherine Stehman-Breen, M.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 213,976. View filing ↗
  • Section 08, Jeffrey Jonas, M.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 210,476. View filing ↗
  • Section 08, Dannielle Appelhans. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 210,476. View filing ↗
  • Section 08, Geoff McDonough, M.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 02, Dannielle Appelhans 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony G. Quinn 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Rhodes 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Charles Rowland 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Catherine Stehman-Breen 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Donald William Nicholson 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey M. Jonas 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gustav Christensen 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ron Cooper 2025-06-04. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Phillip Samayoa 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Phillip Samayoa 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Phillip Samayoa 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Antionette Paone 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Antionette Paone 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Antionette Paone 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2025-07-15. Form 4, filed 2025-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Antionette Paone 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Antionette Paone 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Antionette Paone 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Phillip Samayoa 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Phillip Samayoa 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Phillip Samayoa 2025-10-15. Form 4, filed 2025-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2025-10-31. Form 4, filed 2025-11-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2025-10-31. Form 4, filed 2025-11-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2025-10-31. Form 4, filed 2025-11-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-01-15. Form 4, filed 2026-01-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-02. Form 4, filed 2026-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Dannielle Appelhans 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Dannielle Appelhans 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Dannielle Appelhans 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Dannielle Appelhans 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Dannielle Appelhans 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Dannielle Appelhans 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gustav Christensen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin John Conway 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ron Cooper 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ron Cooper 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ron Cooper 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ron Cooper 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ron Cooper 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ron Cooper 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Yalonda Howze 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey M. Jonas 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Geoff McDonough 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Donald William Nicholson 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony G. Quinn 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Rhodes 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Charles Rowland 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Catherine Stehman-Breen 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Atlas Venture Fund X, L.P. 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Atlas Venture Fund X, L.P. 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Atlas Venture Fund X, L.P. 2026-02-09. Form 4, filed 2026-02-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-06-05. Item 5.07 · say-on-pay result. As reported: 99.06% (votes for as printed: 38,082,392). View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: 99.22% (votes for as printed: 47,772,176). View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-06-09. Item 5.07 · say-on-pay result. As reported: 99.84% (votes for as printed: 57,779,162). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
  • Section 09b board cost (computed). Computed. Cash 466,000 + equity 0 + all other 0 = 466,000, summed across the director compensation table rows.
  • Verve Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Verve Therapeutics, Inc.'s own proxy. As printed: 7,442,663. View filing ↗
  • Graphite Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Graphite Bio, Inc.'s own proxy. As printed: 7,036,009. View filing ↗
  • Cartesian Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cartesian Therapeutics, Inc.'s own proxy. As printed: 4,329,868. View filing ↗
  • Entrada Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Entrada Therapeutics, Inc.'s own proxy. As printed: 3,837,737. View filing ↗
  • Poseida Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Poseida Therapeutics, Inc.'s own proxy. As printed: 3,818,018. View filing ↗
  • Sana Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sana Biotechnology, Inc.'s own proxy. As printed: 2,903,010. View filing ↗
  • Voyager Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Voyager Therapeutics, Inc.'s own proxy. As printed: 2,508,370. View filing ↗
  • Cabaletta Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cabaletta Bio, Inc.'s own proxy. As printed: 2,401,555. View filing ↗
  • Editas Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Editas Medicine, Inc.'s own proxy. As printed: 2,353,655. View filing ↗
  • Precision BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Precision BioSciences, Inc.'s own proxy. As printed: 2,189,467. View filing ↗
  • Tenaya Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Tenaya Therapeutics, Inc.'s own proxy. As printed: 1,881,396. View filing ↗
  • Caribou Biosciences, Inc., Section 10b CEO total. DEFR 14A, filed 2026-05-01. CEO total compensation as printed in Caribou Biosciences, Inc.'s own proxy. As printed: 1,840,965. View filing ↗
  • Generation Bio Co. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Generation Bio Co.'s own proxy. As printed: 1,808,274. View filing ↗
  • Adicet Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Adicet Bio, Inc.'s own proxy. As printed: 1,465,747. View filing ↗
  • Section 10a, Editas Medicine, Inc. reciprocity. DEF 14A. Editas Medicine, Inc. names Generation Bio Co. in its own disclosed peer group (read from its most recent proxy). View filing ↗
Get the full report — $299